NCT05098262View on ClinicalTrials.gov

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2021

Primary Completion Date

January 3, 2022

Study Completion Date

January 3, 2022

Conditions
Healthy
Interventions
DRUG

DA-5210 10/500mg

single dose administration (one tablet once a day)

DRUG

DA-5210-R 10/500mg

single dose administration (one tablet once a day)

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT05098262 - Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State | Biotech Hunter | Biotech Hunter